While it is common knowledge that oncology is an umbrella term used for the branch of science, dedicated wholly to study and treat cancer, not many people have open access to publications that can be helpful when a need arises. Also, the majority of online bio-journals rarely focus on being updated with new technologies and breakthroughs in the oncology department which leaves us with a great divide between a want for information versus readily available matter.
Oncotarget was established in 2010, as a peer-reviewed platform, allows people to get open access to detailed research material in the field of oncology. The sole purpose of this bio-medical journal is to focus primarily on areas specific to cancer, get information on any and all relevant targets while providing an overview of the complexity of this branch of medical science. Check Oncotarget at scimagojr.com
Oncotarget has opted for a power move that has made this bio-journal stand out from the rest. Papers are posted on this platform as frequently as twice a week usually on Tuesdays and Fridays. While some of the research material offers insight on translational along with clinical research, a lot of the other content shared on this platform allow invaluable access to paradigm-shifting and meticulously constructed reviews. Both perspectives and opinions are posted on this platform in a uniquely desirable way. Learn more about Oncotarget at Eurekalert.org.
The archives of Oncotarget are filled with information that has been collected over the years and one of the examples of relevant and factual content posted is the video interview with Dr. Carmelo Nucera. This video along with the detailed written paper focused on explaining various aspects of the reoccurrence of papillary thyroid carcinoma in patients who have been in remission for many months to years. The material posted also highlighted on some interesting facts such as thyroid cancer tends to become drug resistance over time, the new finding by the Harvard Medical School, a plausible treatment with the FDA approved drug palbociclib and how this versatile drug can help in preventing the onset of vemurafenib resistance. The detailed paper posted by Oncotarget also mentioned the results of using this medicine and this information got published on their cover on October 18, 2017.
One of the least publicized medical conditions affecting an estimated 50 million people in the U.S. is arthritis, a general term referring to joint pain or stiffness that can take more than 100 different forms. There are a number of aspects of arthritis that should be understood and explored by those affected by this common medical condition, including the need to self-manage what is essentially a condition without any overall cure; as the leading cause of disability in the nation each person affected by osteoarthritis should take a few steps each day to keep their joints moving and to limit the level of pain they feel with the aid of specialists such as the Osteo Relief Institute.
Osteoarthritis can be characterized by the breaking down of cartilage between the bones in a joint causing the bones to rub and cause pain when moved.(LinkedIn) When a patient is diagnosed with osteoarthritis it is important to take a few steps to reduce the level of problems seen in the condition with the aid of the Osteo Relief Institute; (https://www.facebook.com/osteoreliefinstitutejerseyshore/) a regular daily routine must be attained that includes gentle exercise each morning and night to avoid the stiffness that can occur with osteoarthritis. Other steps that should be remembered are to adjust seating and standing positions throughout each day to avoid stiffness and to reduce the weight of the individual affected to limit the problems caused by excessive size and inactivity.
The Osteo Relief Institute is a specialist in the diagnosis and treatment of a range of arthritis and joint pain issues and is located across the U.S. to make sure the excellent care provided by board certified physicians and surgeons are passed on to as many patients as possible.
The aim of the Osteo Relief Institute is to provide a wide range of treatment and support services that can be used by patients who are looking to avoid surgical options for as long as possible after being diagnosed with osteoarthritis. The Osteo Relief Institute also offers support to patients affected by a range of joint and back pain issues designed to allow as normal a life as possible to be lived for a long period of time.
Eric Lefkofsky is a US businessman who is most well-known for his company Groupon. His latest professional venture is Tempus which could revolutionize how we approach cancer treatments and research in the future. Tempus has a goal to create a genomic database of cancer which would allow physicians to specifically target the therapeutic efforts to combat cancer by comparing cancer patient’s DNA from around the world. After discovering that the technology to create such a database was becoming more accessible and that the data was already there, it seemed like a no-brainer to help establish a database that would help physicians analyze this data.Tempus has teamed up with some of the most reputable hospitals to collect data and has already implemented a 20,000-square ft. lab where gene-sequencing will be performed. Once the database is built, Tempus will provide physicians with software to help them analyze data with ease. Tempus isn’t just a company, it could pave the way to miraculous scientific discoveries surrounding one of the most serious conditions plaguing the world today.
About the Entrepreneur and Businessman Eric Lefkofsky
Aside from Tempus and Groupon, Eric Lefkofsky is a founding partner of Lightbank and a co-founder of Uptake Technologies. Prior to his successful career as a serial entrepreneur and businessman in the Chicago area, Eric Lefkofsky attended the University of Michigan and the University of Michigan Law School.
Tempus isn’t the first technological or medical based venture that Eric has teamed up with or facilitated. Eric and his wife Liz established the Lefkofsky Family Foundation in 2006 to help fast track research, programs, and initiatives aimed at improving the quality of life for people at home and around the world. The Lefkofsky’s have also made significant donations to cancer centers, as well as gastric and breast cancer research. If Tempus is as successful as his previous ventures, you can be sure that it is sure to make waves throughout the medical, scientific, and technological communities.
Eric Lefkofsky has used his innovative mind to create companies that have made positive changes in the world. Lefkofsky is a Michigan born man who graduated from the University of Michigan. Lefkofsky has a net worth of about 1.97 billion dollars. He is a person who has used his influence and wealth to help others. Tempus is a company that was created by Eric Lefkofsky. This is a company that was created to help those individuals who are suffering from cancer. The general treatment for cancer is the use of radiation or chemotherapy. These are treatments that are made to help cure certain types of cancers, but each individual is different when it comes to their cancer diagnosis. An individual has a much better chance of getting a cure if they get a medication that is tailored suited to their genetic makeup. Targeted cancer care is the total concept of Tempus.
Tempus works with different hospitals like Penn Hospital and the Mayo Clinic to approach the genomic data of each individual. Their technology uses sequencing to get a better understanding of each patient’s type of cancer. Using Tempus technology, a physician can analyze their patient’s DNA on a molecular level, and they can find a personal treatment for them. This is the only type of medical technology of its kind. Tempus assists doctors in making medical decisions that can treat patients in an effective manner.
Another monumental achievement of Eric Lefkofsky and his wife is the Lefkofsky Family Foundation. This is a foundation that was created to work in tandem with other charities. The Lefkofsky Family Foundation is a foundation that gives to the arts, education, and human rights. This foundation has the goal of helping to improve the quality of life of all human beings. The Lefkofsky Family Foundation is also dedicated to their community. The Lefkofsky family is a family that gives of their funds and their time to promote growth and culture in their local community.
The ACD’s, or antibody drug conjugates are intended to lessen the toxicity in chemotherapy while enhancing anti-tumor therapies. Seattle Genetics was incorporated in 1998. Its flagship product Adcesis is now available in 50 countries.
Dr. Clay Siegall is the company’s board chairman and CEO. He co-founded the company in 1998. Dr. Siegall is responsible for helping Seattle Genetics introduce a new line of cancer treatment drugs that fight tumors. Seattle Genetics has collaborated with a number of pharmaceutical companies including Bayer, Genetech, Benmab and Unem Therapeutics. Seattle Genetics has raised more than $300 million in capital to help with drug studies and exclusive collaboration efforts.
Under the leadership of Dr. Siegall, Seattle Genetics has acquired a number of strategic licenses. Before Seattle Genetics, Dr. Siegall worked for Bristol Meyers Squibb. He also worked at the National Cancer Institute and the National Institutes of Health. Dr. Siegall has an extensive educational background. He graduated from the University of Maryland with a B.S. in Zoology. He then attended George Washington University and received a Ph.D in Genetics.
Dr. Siegall sits on a number of boards including Ultragenics Pharmaceuticals Inc., Aldo Pharmaceuticals and Mirna Theraputics. He is the holder of 15 patents and been published more than 70 times. Dr. Siegall has won numerous awards for excellence including the University of Maryland Alumnus of the Year and the Ernst and Young Entrepreneur of the Year for 2012.